Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

How to Increase Engagement During Virtual Events

Tip #6 - Individualizing a virtual event for your participants makes it more likely for them to attend and gain something valuable from the event. Learn how else you can...

Impetus Digital

How to Increase Engagement During Virtual Events

Tip #5 - Do you want to increase engagement during virtual events? To allow deep-dives into new data, discuss gaps/needs, or brainstorm new ideas, moderated small-group breakout sessions and workshops...

Impetus Digital

- PMLiVE

Sanofi and Innate Pharma expand cancer therapeutics collaboration

The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology

- PMLiVE

FDA approves Ferring’s Adstiladrin as first gene therapy for bladder cancer

Non-muscle-invasive bladder cancer represents around 75% of all new bladder cancer cases

Biogen Idec building

Biogen and Genentech sign royalty agreement for blood cancer drug glofitamab

Genentech will have sole decision-making rights on glofitamab's commercialisation in the US

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

ICR twin study indicates childhood leukaemia begins in the womb

The study, published in Leukemia, will help clinicians advise parents of twins with ALL

- PMLiVE

The challenges of the proposed Data Protection and Digital Information Bill

Why the new Bill may cause more complexity and confusion for businesses operating outside the UK

- PMLiVE

Mind the gender gap: how marcomms can tackle gender health inequality

By Kesha Tansey and Emma Moss

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer

The treatment has been recommended for use within a managed access arrangement

- PMLiVE

FDA lifts partial clinical hold on bluebird bio’s sickle cell gene therapy studies

The company can now resume the enrolment and treatment of patients aged two to 17 years

- PMLiVE

iOnctura awarded €17.5m from EIC Accelerator for novel pancreatic cancer therapy

The company dosed the first patient in a phase 1b study of IOA-289 earlier this month

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links